公开(公告)号：WO2022072156A1

公开(公告)日：2022-04-07

申请号：PCT/US2021/050934

申请日：2021-09-17

Applicant: ORTHOTROPHIX, INC.

Inventor： MILLER, Meghan ,  KUMAGAI, Yoshinari ,  ROSEN, David ,  MCGUIRE, Dawn

IPC: A61K9/00 ,  A61K38/00 ,  A61K38/03 ,  A61K38/16 ,  A61P19/00 ,  A61P19/08

Abstract: Compounds, pharmaceutical compositions, and a method of treating hard tissue diseases and disorders are disclosed. The compounds may be a peptide and is structured to bind integrin αVβ3 expressed by osteocytes and by selective binding to the cell surface integrin on hard tissue forming cells regulate three-dimensional bone shape, cartilage formation and repair.

公开(公告)号：WO2020176276A1

公开(公告)日：2020-09-03

申请号：PCT/US2020/018359

申请日：2020-02-14

Applicant: ZOGENIX INTERNATIONAL LIMITED ,  MILLET, David ,  GALER, Bradley S.

Inventor： MILLET, David ,  GALER, Bradley S.

IPC: A61P25/08 ,  A61K9/00 ,  A61P25/00

Abstract: Described herein is a method of improving seizure control in a patient experiencing uncontrolled seizures persisting 10 minutes or more, comprising administering fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, at a dose of from 0.2 to 1.2 m/kg/day for a period of about 12 hours to about 7 days to a patient having been put into a therapeutic, medically-induced coma via a general anesthetic; and after about 12 hours to about 7 days, weaning the patient from the general anesthetic and assessing whether the seizure control has improved as compared to a pre-treatment time point. The patient experiencing seizures may have epilepsy or epileptic encephalopathy that has led to established status epilepticus (SE), refractory status epilepticus (RSE) or super-refractory status epilepticus (SRSE).

公开(公告)号：WO2019067413A1

公开(公告)日：2019-04-04

申请号：PCT/US2018/052580

申请日：2018-09-25

Applicant: ZOGENIX INTERNATIONAL LIMITED ,  FARFEL, Gail ,  LOCK, Michael ,  GALER, Bradley S. ,  MORRISON, Glenn ,  BOYD, Brooks M.

Inventor： FARFEL, Gail ,  LOCK, Michael ,  GALER, Bradley S. ,  MORRISON, Glenn ,  BOYD, Brooks M.

IPC: A61K31/137 ,  A61P25/08 ,  A61K45/06

CPC classification number: A61P25/08 ,  A61K31/137 ,  A61K45/06 ,  A61K2300/00

Abstract: A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.

公开(公告)号：WO2018080795A1

公开(公告)日：2018-05-03

申请号：PCT/US2017/056111

申请日：2017-10-11

Applicant: GLYKON TECHNOLOGIES GROUP, LLC

Inventor： CLOUATRE, Dallas L. ,  CLOUATRE, Daniel E.

IPC: A61J3/00 ,  A61J3/07 ,  A61K9/08 ,  A61K31/00 ,  A61K47/10

Abstract: A capsule oral delivery system is disclosed. The system includes an outer capsule completely enclosing an inner content, or a hard shell comprised of hydroxypropyl methylcellulose (HPMC) enclosing the content. A liquid formulation forming the inner content of the outer capsule is comprised of a hydroxycitric acid (HCA) salt, water, and glycerol, with the HCA being completely dissolved in the water and glycerol which may be the only components present in the capsule, which may be administered to a patient in a method of treatment to cause weight loss when repeatedly administered.

Abstract translation: 公开了一种胶囊口服递送系统。 该系统包括完全封闭内容物的外胶囊或包封内容物的由羟丙基甲基纤维素（HPMC）组成的硬壳。 形成外胶囊内含量的液体制剂由羟基柠檬酸（HCA）盐，水和甘油组成，其中HCA完全溶于水和甘油中，甘油可以是胶囊中存在的唯一组分，其中 可以在治疗方法中给患者施用以在重复施用时引起体重减轻。

公开(公告)号：WO2017035267A1

公开(公告)日：2017-03-02

申请号：PCT/US2016/048470

申请日：2016-08-24

Applicant: ZOGENIX INTERNATIONAL LIMITED

Inventor： FARR, Stephen J. ,  GALER, Bradley S.

IPC: A61K31/135 ,  A61K31/137

CPC classification number: A61K31/137 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/7023 ,  A61K31/19 ,  A61K31/357 ,  A61K31/551 ,  A61K45/06 ,  A61K2300/00

Abstract: A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.

Abstract translation: 通过对该患者施用有效剂量的芬氟拉明或其药学上可接受的盐，治疗和/或预防患者例如先前诊断为Lennox综合征的患者中也称为Lennox综合征的Lennox-Gastaut综合征（LGS）的症状的方法 。 Lennox综合征患者以小于约2.0至约0.01mg / kg /天的优选剂量治疗。

公开(公告)号：WO2015061025A1

公开(公告)日：2015-04-30

申请号：PCT/US2014/059092

申请日：2014-10-03

Applicant: ARADIGM CORPORATION

Inventor： CIPOLLA, David ,  GONDA, Igor

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/0078 ,  A61K31/496 ,  A61K47/10 ,  A61K47/26

Abstract: Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Abstract translation: 用于配制和立即和持续释放的脂质体产品的组合物的方法，其包含与脂质体相互作用以实现药物释放的表面活性剂，以及用于治疗呼吸道感染和其它医学病症的递送剂，以及与其结合使用的装置和制剂 被描述。

公开(公告)号：WO2014159169A1

公开(公告)日：2014-10-02

申请号：PCT/US2014/022338

申请日：2014-03-10

Applicant: FLOW PHARMA, INC.

Inventor： RUBSAMEN, Reid, M.

IPC: A61F6/06

CPC classification number: A61K9/146 ,  A61K9/06 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/675

Abstract: Formulations are disclosed which are comprised of tenofovir particles, and a biocompatible gel having the particles dispersed therein. The gel may be comprised of a flavoring agent and one or more compounds which generate heat. The particles may be provided in a plurality of groups (2, 3 or more) of different size spheres. The spheres may be comprised of tenofovir alone or in combination with emtricitabine and a controlled release polymer such as poly lactic glycolic acid (PLGA) or other suitable, biocompatible material.

Abstract translation: 公开了由替诺福韦颗粒和分散有颗粒的生物相容性凝胶组成的制剂。 凝胶可以由调味剂和一种或多种产生热的化合物组成。 颗粒可以以不同大小的球体的多个组（2,3个或更多个）提供。 球体可以单独使用替诺福韦或与恩曲他滨组合和控释聚合物如聚乳酸乙醇酸（PLGA）或其它合适的生物相容性材料组合。

公开(公告)号：WO2014022570A1

公开(公告)日：2014-02-06

申请号：PCT/US2013/053043

申请日：2013-07-31

Applicant: ZOGENIX, INC.

Inventor： HARTMAN, Andrew ,  RUBINO, Christopher ,  ROBINSON, Cynthia

IPC: A61K9/22 ,  A61K31/485 ,  A61P25/04

CPC classification number: A61K9/0087 ,  A61K9/1676 ,  A61K9/5026 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/46 ,  A61K31/485

Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition comprises a multiparticulate modified release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules as the primary package. The oral dosage units are supplied as part of a kit, which also includes a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment.

Abstract translation: 用于止痛活性药物成分的延长释放组合物，其可以是阿片样物质，优选为氢可酮作为唯一活性成分。 延长释放组合物包含多颗粒改性释放组合物，其可以是口服剂型中包含的珠粒形式，例如明胶胶囊作为主要包装。 口服剂量单位作为试剂盒的一部分提供，其还包括作为市售产品销售的包装。 主包装和包装插入物包含在可选的二次包装中，包装插页不包含警告，剂量说明或专门针对患有轻度，中度或重度肝损伤的患者的剂量表。

公开(公告)号：WO2010005550A1

公开(公告)日：2010-01-14

申请号：PCT/US2009/003965

申请日：2009-07-06

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  COHEN, Bruce

Inventor： COHEN, Bruce

IPC: C12Q1/48

CPC classification number: G01N21/6428 ,  B82Y15/00 ,  B82Y20/00 ,  B82Y30/00 ,  G01N2021/6439

Abstract: Semiconductor nanocrystals known as quantum dots (QD) are caged by being associated with a molecule such as an orth-Nitrobenzyl (ONB) group. The luminescence of the QD is suppressed until activated by violet or ultra violet light.

Abstract translation: 称为量子点（QD）的半导体纳米晶体通过与诸如邻硝基苄基（ONB）基团的分子相关而笼罩。 QD的发光被抑制直到由紫罗兰或紫外线激发。

公开(公告)号：WO2008094444A2

公开(公告)日：2008-08-07

申请号：PCT/US2008/000938

申请日：2008-01-23

Applicant: LAURIMED LLC ,  SAAL, Jeffrey Alan ,  SAAL, Joel Stuart ,  DUBOIS, Brian R. ,  CHRISTIAN, Jeff

Inventor： SAAL, Jeffrey Alan ,  SAAL, Joel Stuart ,  DUBOIS, Brian R. ,  CHRISTIAN, Jeff

CPC classification number: A61B17/3421 ,  A61B17/320783 ,  A61B90/37 ,  A61B2017/00261 ,  A61B2017/003 ,  A61B2017/00867 ,  A61B2017/2905

Abstract: A cutting device for performing a selective discectomy is disclosed along with a method for using the device whereby the device is inserted into the intervertebral disc at a point contralateral, anterior, or anterolateral to a site of herniation. The device includes a shaft with a cutting mechanism at its distal end. Control wire(s) attached to either or both shafts may be used to position cutting components and perform the discectomy.

Abstract translation: 公开了一种用于执行选择性椎间盘切除术的切割装置以及使用该装置的方法，由此将装置插入到椎间盘中，在疝位点的对侧，前侧或前外侧的点处。 该装置包括在其远端具有切割机构的轴。 连接到任一轴或两个轴的控制线可用于定位切割部件并执行椎间盘切除术。